Loading...
•
Jun 30, 2025
Aeterna Zentaris Q2 2025 Earnings Report
Aeterna Zentaris, now operating as COSCIENS Biopharma, reported increased revenue and higher net loss in Q2 2025 due to restructuring and merger-related activities.
Key Takeaways
COSCIENS Biopharma posted $2.7 million in revenue for Q2 2025, with a net loss of $2.4 million driven by integration and restructuring efforts. The company reduced operating expenses by 28% and completed a strategic review of its pipeline while preparing to delist from Nasdaq.
Revenue for Q2 2025 was $2.7 million, up from $2.3 million YoY.
Net loss rose to $2.4 million due to merger and restructuring costs.
Operating expenses declined by 28% compared to Q2 2024.
Cash balance stood at $9.3 million at quarter-end.
Forward Guidance
COSCIENS aims to achieve long-term growth through portfolio optimization, ongoing cost controls, and completion of its Phase 2a study while transitioning off Nasdaq.
Positive Outlook
- Completed Phase 1 trial for AvenActive with no major safety issues.
- Phase 2a AvenActive study expected to conclude in Q3 2025.
- Board and CEO restructuring to drive operational efficiency.
- Macrilen pediatric strategy under FDA review with Type C meeting planned.
- Zero-based budgeting and cost reductions expected to realize full savings in 2026.
Challenges Ahead
- Company will voluntarily delist from Nasdaq, reducing U.S. investor access.
- Restructuring efforts include 27% workforce reduction.
- Phase 3 DETECT trial for Macrilen failed to meet primary endpoint.
- No direct-to-consumer platform limits immediate commercialization.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...